Contrasting Enanta Pharmaceuticals (ENTA) & The Competition

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Enanta Pharmaceuticals to related companies based on the strength of its earnings, valuation, analyst recommendations, risk, institutional ownership, profitability and dividends.

Insider and Institutional Ownership

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Enanta Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals’ competitors have a beta of -0.05, suggesting that their average stock price is 105% less volatile than the S&P 500.

Valuation & Earnings

This table compares Enanta Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Enanta Pharmaceuticals $63.00 million -$81.89 million -3.61
Enanta Pharmaceuticals Competitors $3.56 billion $3.18 billion 558.05

Enanta Pharmaceuticals’ competitors have higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Enanta Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enanta Pharmaceuticals -108.33% -59.48% -21.76%
Enanta Pharmaceuticals Competitors -2,391.70% -206.08% -14.88%

Analyst Recommendations

This is a breakdown of current recommendations for Enanta Pharmaceuticals and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enanta Pharmaceuticals 1 0 2 0 2.33
Enanta Pharmaceuticals Competitors 7850 13806 25842 1039 2.41

Enanta Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 130.15%. As a group, “Pharmaceuticals” companies have a potential upside of 26.79%. Given Enanta Pharmaceuticals’ higher probable upside, equities research analysts plainly believe Enanta Pharmaceuticals is more favorable than its competitors.

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.